Oct 30, 2024
Galapagos reports strong Q3 progress, including advancing CAR-T programs to clinical trials. Cell therapy, non-Hodgkin lymphoma, cancer (Source)
Oct 24, 2024
Coeptis and Deverra Collaborate to Combat Viral Infections and Strengthen Pandemic Preparedness with Allogeneic NK Cell Therapy. (Source)
Lyell Immunopharma to Acquire ImmPACT Bio, Prioritizing Next-Gen CAR T-cell Therapies. (Source)
Oct 23, 2024
Interius BioTherapeutics Doses First Patient in Phase 1 Trial for In Vivo CAR Gene Therapy Targeting B-Cell Malignancies. (Source)
Lyell Immunopharma to Acquire ImmPACT Bio, Prioritizing Next-Gen CAR T-cell Therapies
March Biosciences Raises $28.4M in Series A Funding. Cell therapy, T-cell lymphoma, CAR-T (Source)
Oct 22, 2024
AvenCell secures $112 million in Series B funding led by Novo Holdings. Cell therapy, myeloid leukaemia, CAR-T, cancer (Source)
Be Bio’s $82M Funding Boosts Transition to Clinical Stage Development. (Source)
Oct 18, 2024
REGIMUNE, a company developing regulatory T cell targeting drugs for immunotherapy, and Kiji Therapeutics, specializing in engineered IPSC-MSC therapies for inflammatory diseases, have announced plans to merge. (Source)
FibroBiologics, Inc. and Charles River Laboratories have partnered to develop and manufacture CYWC628, fibroblast-based Cell-based therapy for diabetic foot ulcers. (Source)
Oct 17, 2024
Capricor Therapeutics, a biotech company specializing in innovative cell and exosome-based therapies for rare diseases, has successfully priced a public offering of common stock valued at approximately $75 million. (Source)
Eterna Therapeutics Inc. and Factor Bioscience Limited have partnered to develop innovative cell therapies for cancer, rare diseases, and autoimmune conditions. (Source)
Poseida Therapeutics announces a new CAR-T development candidate with Roche. Cell therapy, cancer, multiple myeloma, CAR-T, allogeneic (Source)
Oct 16, 2024
Matica Bio and Mongoose Bio have formed a strategic partnership to advance the development of TCR-T cell therapy. (Source)
Oct 15, 2024
Seraxis Inc., a clinical-stage regenerative medicine company (developed stem cell lines), has secured FDA approval for a Phase I/II clinical trial of its innovative islet replacement therapy, SR-02. SR-02 is the first reprogrammed stem cell-derived pancreatic product candidate authorized by the FDA for human testing as a potential cure for insulin-dependent type 1 diabetes. (Source)
Tolerance Bio, focused on immune-mediated diseases, has secured $17.2 million in seed funding to develop thymus-based therapies. They’re poised to advance their allogeneic thymus iPSC-based cell therapy. Cancer, autoimmune, induced pluripotent stem cells (Source)
invIOs secures €8.2 million in Series A funding to advance its immuno-oncology pipeline. The company’s innovative cell therapy platform, EPiC, enables the development of personalized cell-based treatments that harness the patient’s immune system to combat solid tumors. (Source)
Oct 11, 2024
Capricor Therapeutics, developing transformative cell and exosome-based therapeutics for rare diseases, announced positive three-year data from its deramiocel Phase 2 clinical trial in Duchenne muscular dystrophy (DMD). allogeneic cell therapy (Source)
Oct 10, 2024
Immatics Shares Phase 1b Data on IMA203 for Melanoma and Updates SUPRAME Phase 3 Trial. Cell therapy, metastatic melanoma, solid tumor, cancer, autologous TCR (Source) Also, On Oct 10, 2024, Immatics Announces Proposed $150 Million Public Offering (Source)
Oct 09, 2024
Nona Biosciences and OverT Bio have formed a strategic partnership to develop cutting-edge cell therapies for solid tumors. By combining Nona’s proprietary fully human HCAb Harbour Mice® platform with OverT Bio’s expertise, the collaboration aims to create novel cell therapies using Nona’s innovative NonaCarFxTM platform. (Source)
Oct 08, 2024
Aurigene Oncology reports positive Phase 1 results for India’s first CAR-T therapy for multiple myeloma. Cell therapy (Source)
MiNK Therapeutics, allogeneic off-the-shelf invariant natural killer T (iNKT) cell therapies, and Autonomous Therapeutics, specializing in the creation of novel, disease-activated RNA medicines, have announced a strategic research collaboration. The joint effort aims to effectively target and treat metastatic tumors. (Source)
Oct 07, 2024
Rege Nephro secured $17M Series B funding, with $15M already received. Cell therapy, kidney disease, induced pluripotent stem cells (iPSC, iPS cells) (Source)
